Product Datasheet

www.leinco.com



excellence in early discovery research™

Anti-Mouse CD223 (LAG-3)

Purified *in vivo* PLATINUM™ Functional Grade Monoclonal Antibody


Product Information

Product No.: C2852 Clone: C9B7W

RRID: AB 2829608

Isotype: Rat IgG1

Storage: Sterile 2-8°C



Lane 1: 20 ug reduced A-20 whole cell lysate (Prod. No. A232)

Lane 2: 10 ug reduced A-20 whole cell lysate (Prod. No. A232)

Lane 3: 2 ug reduced recombinant mouse CD223 (LAG-3)

Lane 4: 1 ug reduced recombinant mouse CD223 (LAG-3)

Primary: anti-mouse CD223 (LAG-3) antibody (C9B7W) at 8 ug/ml (Prod. No. C2852)

Secondary: HRP labeled goat anti-rat at 1:1000 dilution (Prod. No. R1215)

Predicted band size: 70-90 kDa

Product Description

Specificity:

Clone C9B7W recognizes and specifically binds to an epitope in the D2 domain of CD223. Antigen Distribution:

CD223 is expressed on T regulatory cells, activated T cells and NK cells.

Background:

LAG-3 is a 70-kD, type-I transmembrane glycoprotein within the Ig superfamily with four extracellular Ig-like domains (D1 to D4) and is structurally homologous to CD4. LAG-3 is a cell surface molecule with various biologic effects on T cell function. It has been reported to be involved in Treg suppressive function. It negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar manner to CTLA-4 and PD-1. Human LAG-3 is approximately 70% homologous with murine LAG3, and it binds MHC class II molecules with higher affinity than CD4. As an immune checkpoint receptor, LAG-3 is the target of various drug development programs seeking to expand treatments for cancer and autoimmune disorders. In its soluble form, LAG-3 is being developed as a cancer drug. As an antagonist, LAG-3 antibody can activate T effector cells via the downregulation of the LAG-3 inhibiting signal into pre-activated LAG-3+ cells. In addition, it can inhibit antigen-specific Treg suppressive activity. As an agonist antibody, it can be used to diminish an autoimmune response and is currently being investigated for the treatment of plaque psoriasis.

Known Reactivity Species:

Mouse

Format:

Purified in vivo Functional Grade, in vivo PLATINUM™

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity

≥98% monomer by analytical SEC, >95% by SDS Page

Endotoxin

< 0.5 EU/mg as determined by the LAL method

Storage and Stability

Functional grade preclinical antibodies may be stored sterile as received at $2-8^{\circ}$ C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at $\leq -70^{\circ}$ C.

Avoid Repeated Freeze Thaw Cycles.

Product Datasheet

www.leinco.com



Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using *in vitro* cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco's Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Country of Origin

USA